Literature DB >> 17102620

IKKalpha regulates the mitotic phase of the cell cycle by modulating Aurora A phosphorylation.

ShaShi Prajapati1, Zheng Tu, Yumi Yamamoto, Richard B Gaynor.   

Abstract

The IKK complex includes two catalytic components, IKKalpha and IKKbeta, in addition to the scaffold protein IKKgamma/NEMO. Even though IKKalpha and IKKbeta share significant sequence homology, they have distinct biological roles with IKKbeta regulates the classical pathway of NF-kappaB activation and IKKalpha regulates the alternative pathways. In addition, it has been shown that the IKKs regulate the proliferation of both normal and tumor cells; however, the mechanisms by which the IKKs regulate the cell cycle remain to be further defined. Here, we demonstrate that IKKalpha, but not IKKbeta, has role in regulating the M phase of the cell cycle. IKKalpha siRNA knock -down resulted in increased numbers of cells in the G(2)/M phase of the cell cycle as compared to control and IKKbeta siRNA transfected HeLa cells. This effect was associated with upregulation of cyclin B1 and Plk1 protein levels and increased histone H3 phosphorylation, consistent with a potential role of IKKalpha in the regulation of M phase regulatory factors. IKKalpha was found to be associated with Aurora A in the centrosome and regulate Aurora A phosphorylation at threonine residue 288, a site which is important in modulating its kinase activity. Taken together, these data provide the evidence that IKKalpha regulates the M phase of the cell cycle by modulating Aurora A phosphorylation and activation leading to the regulation of the M phase of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17102620     DOI: 10.4161/cc.5.20.3359

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  22 in total

1.  Alternative nuclear functions for NF-κB family members.

Authors:  Lluís Espinosa; Anna Bigas; Maria Carmen Mulero
Journal:  Am J Cancer Res       Date:  2011-02-16       Impact factor: 6.166

2.  MK615 inhibits pancreatic cancer cell growth by dual inhibition of Aurora A and B kinases.

Authors:  Toshie Okada; Tokihiko Sawada; Tatsushi Osawa; Masakazu Adachi; Keiichi Kubota
Journal:  World J Gastroenterol       Date:  2008-03-07       Impact factor: 5.742

Review 3.  Inhibitory kappa B Kinases as targets for pharmacological regulation.

Authors:  Carly Gamble; Kathryn McIntosh; Rebecca Scott; Ka Ho Ho; Robin Plevin; Andrew Paul
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

4.  Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-κB pathway.

Authors:  Sampath Ramachandiran; Arsene Adon; Xiangxue Guo; Yi Wang; Huichen Wang; Zhengjia Chen; Jeanne Kowalski; Ustun R Sunay; Andrew N Young; Theresa Brown; Jessica C Mar; Yuhong Du; Haian Fu; Karen P Mann; Yasodha Natkunam; Lawrence H Boise; Harold I Saavedra; Izidore S Lossos; Leon Bernal-Mizrachi
Journal:  Int J Cancer       Date:  2014-11-11       Impact factor: 7.396

5.  The scaffold protein TANK/I-TRAF inhibits NF-kappaB activation by recruiting polo-like kinase 1.

Authors:  Wanqiao Zhang; Jian Wang; Ying Zhang; Yanzhi Yuan; Wei Guan; Chaozhi Jin; Hui Chen; Xiaohui Wang; Xiaoming Yang; Fuchu He
Journal:  Mol Biol Cell       Date:  2010-05-19       Impact factor: 4.138

6.  An IKKα-nucleophosmin axis utilizes inflammatory signaling to promote genome integrity.

Authors:  Xiaojun Xia; Shuang Liu; Zuoxiang Xiao; Feng Zhu; Na-Young Song; Ming Zhou; Bigang Liu; Jianjun Shen; Kunio Nagashima; Timothy D Veenstra; Sandra Burkett; Mahesh Datla; Jami Willette-Brown; Haifa Shen; Yinling Hu
Journal:  Cell Rep       Date:  2013-11-27       Impact factor: 9.423

7.  Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.

Authors:  Teru Hideshima; Dharminder Chauhan; Tanyel Kiziltepe; Hiroshi Ikeda; Yutaka Okawa; Klaus Podar; Noopur Raje; Alexei Protopopov; Nikhil C Munshi; Paul G Richardson; Ruben D Carrasco; Kenneth C Anderson
Journal:  Blood       Date:  2009-03-06       Impact factor: 22.113

8.  IRF6 in development and disease: a mediator of quiescence and differentiation.

Authors:  Caleb M Bailey; Mary J C Hendrix
Journal:  Cell Cycle       Date:  2008-04-29       Impact factor: 4.534

Review 9.  Targeting IκappaB kinases for cancer therapy.

Authors:  Nikee Awasthee; Vipin Rai; Srinivas Chava; Palanisamy Nallasamy; Ajaikumar B Kunnumakkara; Anupam Bishayee; Subhash C Chauhan; Kishore B Challagundla; Subash C Gupta
Journal:  Semin Cancer Biol       Date:  2018-02-24       Impact factor: 15.707

10.  Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival.

Authors:  Jin-E Yao; Min Yan; Zhong Guan; Chao-Bin Pan; Liang-Ping Xia; Chuan-Xing Li; Li-Hui Wang; Zi-Jie Long; Yan Zhao; Ming-Wei Li; Fei-Meng Zheng; Jie Xu; Dong-Jun Lin; Quentin Liu
Journal:  Mol Cancer       Date:  2009-11-05       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.